Group 1 - The article discusses Verastem (VSTM) and its recent challenges, particularly the setback in targeting KRAS G12C NSCLC through the RAMP-203 trial [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis of pharmaceutical companies through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Verastem or the biotech industry [1][3][4]

Core Insights - Verastem Oncology announced that multiple abstracts, including late-breaking ones, have been accepted for presentation at the AACR Annual Meeting 2026, highlighting the potential of their investigational asset VS-7375 in treating KRAS G12D-driven cancers [1][2] Group 1: Research Findings - Preclinical research demonstrated that VS-7375, a dual ON/OFF inhibitor, showed stronger and more durable tumor regressions in KRAS G12D pancreatic cancer models compared to ON-only G12D or pan-RAS inhibitors [1][4] - In the KP4 KRAS G12D pancreatic cancer model, VS-7375 maintained sustained tumor regression (mean tumor volume ~80 mm by day 30), while other inhibitors lost anti-tumor activity, showing mean tumor volume >850 mm by day 30 [4] Group 2: Presentation Details - Late-breaking abstracts will be presented on April 20, 2026, including findings on the efficacy of VS-7375 in combination with PRMT5 inhibition in pancreatic cancer [3] - Regular abstracts will be available on April 22, 2026, showcasing VS-7375's potent anti-tumor activity as a single agent and in combination with other agents [3] Group 3: Clinical Development - VS-7375 is currently in Phase 1/2 clinical trials, initiated in June 2025, evaluating its safety and efficacy in patients with advanced KRAS G12D mutant solid tumors [7] - The FDA granted Fast Track Designation to VS-7375 for first-line treatment of KRAS G12D-mutated locally advanced or metastatic pancreatic adenocarcinoma [7] Group 4: Collaboration and Strategy - Verastem's collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers, with VS-7375 being the lead program [8]

Core Viewpoint - Verastem (VSTM) shows significant upside potential with a mean price target of $16.57, indicating a 159.3% increase from its current trading price of $6.39 [1] Price Targets - The mean estimate consists of seven short-term price targets with a standard deviation of $1.81, where the lowest estimate is $14.00 (119.1% increase) and the highest is $19.00 (197.3% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment - Analysts are optimistic about VSTM's earnings prospects, as indicated by upward revisions in EPS estimates, which have shown a strong correlation with stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 3.2% due to one upward revision and no negative revisions in the last 30 days [12] Zacks Rank - VSTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, they should be approached with skepticism as they may not reliably indicate actual stock price movements [10]

Core Insights - The company is focused on the development of transcript-related projects, indicating a commitment to enhancing its offerings in this area [1] Group 1 - The company publishes thousands of quarterly earnings calls each quarter, showcasing its extensive coverage and growth in the transcript publishing sector [1]

分组1 - Verastem reported a quarterly loss of $0.5 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.49, but an improvement from a loss of $1.33 per share a year ago, indicating an earnings surprise of -2.04% [1] - The company generated revenues of $17.54 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.20%, compared to zero revenues in the same quarter last year [2] - Verastem shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's decline of 0.4% [3] 分组2 - The earnings outlook for Verastem is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.46 on revenues of $22.8 million, and for the current fiscal year at -$1.86 on revenues of $134.45 million [7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the bottom 44% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] - Foghorn Therapeutics Inc., another company in the same industry, is expected to report a quarterly loss of $0.28 per share, with revenues projected to be $8.05 million, reflecting a year-over-year increase of 181.5% [9]

Financial Data and Key Metrics Changes - The company reported $17.5 million in net product revenue for Q4 2025 and $30.9 million for the full year, marking a significant achievement following the FDA approval of its treatment for KRAS-mutated recurrent low-grade serous ovarian cancer [5][31] - The cost of sales for Q4 2025 was $2.6 million, with total R&D expenses at $31.7 million for the quarter and $114.6 million for the full year, driven by ongoing clinical trials [31][32] - The non-GAAP adjusted net loss for Q4 2025 was $39.8 million, compared to a loss of $29.3 million in Q4 2024, indicating increased investment in growth [33] Business Line Data and Key Metrics Changes - The launch of AVMAPKI FAKZYNJA CO-PACK has seen steady growth, with nearly 300 prescribers by February 2026, and over half of total prescriptions coming from academic centers [16][66] - The company is focusing on expanding its prescriber base and increasing comfort among oncologists to use the CO-PACK as a first recurrence treatment [8][20] Market Data and Key Metrics Changes - The NCCN guidelines did not expand recommendations for the treatment to include patients with KRAS wild-type recurrent LGSOC, which the company views as a challenge but not a deterrent to its launch trajectory [6][42] - The payer coverage remains strong across all LGSOC-prescribed patients, with rapid prior authorization approval times of 12-14 days [17][66] Company Strategy and Development Direction - The company aims to maximize the commercial launch of AVMAPKI FAKZYNJA CO-PACK, generate data for VS-7375, and continue executing the RAMP-301 trial [37][39] - The focus is on maintaining prudent capital management while advancing clinical programs and ensuring the LGSOC franchise becomes self-sustaining by the second half of 2026 [12][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial execution and the potential for the LGSOC franchise to be self-sustaining, supported by revenues from CO-PACK sales [12][35] - The company is committed to advancing clinical evidence and expanding its treatment options for patients with RAS-driven cancers, despite challenges in the current regulatory environment [8][39] Other Important Information - The company has extended its cash runway into the first half of 2027, allowing it to advance near-term milestones without immediate need for additional financing [12][35] - The company is exploring non-dilutive financing opportunities to support its growth while managing expenses carefully [12][64] Q&A Session Summary Question: Insights on NCCN non-update and reimbursement for wild-type patients - Management expressed disappointment regarding the NCCN decision and noted that they are securing reimbursement regardless of KRAS mutation status, emphasizing ongoing efforts to promote the treatment based on clinical data [41][42] Question: Safety and dose modifications for VS-7375 - Management reported low dose modifications and discontinuations, indicating that patients are tolerating the drug well, and emphasized the importance of long-term tolerability in chronic cancer treatments [47][49] Question: Future financing strategies - Management indicated that the LGSOC franchise is expected to be self-sustaining, and any additional capital raised will be based on positive data from the G12D program, with a focus on non-dilutive financing options [62][64] Question: Prescribing dynamics for CO-PACK - Management noted that approximately 75% of top institutions have adopted the CO-PACK, with a consistent split of prescriptions between GynOncs and MedOncs, and highlighted the effectiveness of the Verastem Cares program in facilitating patient access [66][67]

Financial Data and Key Metrics Changes - The company reported $17.5 million in net product revenue for Q4 2025 and $30.9 million for the full year, marking a successful commercial launch following FDA approval [5][31] - Cost of sales for Q4 2025 was $2.6 million, with total R&D expenses at $31.7 million for the quarter and $114.6 million for the full year [31][32] - The non-GAAP adjusted net loss for Q4 2025 was $39.8 million, compared to $29.3 million in Q4 2024, indicating an increase in losses year-over-year [33] Business Line Data and Key Metrics Changes - The launch of AVMAPKI FAKZYNJA for KRAS-mutated recurrent low-grade serous ovarian cancer has seen steady growth, with nearly 300 prescribers by February 2026 [16][66] - The split of prescriptions remains approximately 60% from Gynecologic Oncologists (GynOncs) and 40% from Medical Oncologists (MedOncs), consistent with previous quarters [16][66] - The company is focusing on expanding its prescriber base and increasing comfort among prescribers to use the combination therapy [8][19] Market Data and Key Metrics Changes - The company has seen strong payer coverage across all LGSOC-prescribed patients, regardless of mutational status, with rapid prior authorization approval times of 12-14 days [17][66] - The NCCN guidelines did not expand recommendations for certain patient groups, but the company remains confident in securing reimbursement for wild-type patients [6][42] Company Strategy and Development Direction - The company aims to maximize the commercial launch of AVMAPKI FAKZYNJA, generate data for VS-7375, and maintain prudent capital management [37][39] - The focus is on expanding the clinical evidence for both the LGSOC franchise and the VS-7375 program, with plans for new promotional campaigns and educational programs [20][38] - The company is prioritizing high-value opportunities while managing expenses, with expectations that the LGSOC franchise will be self-sustaining in the second half of 2026 [12][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial execution and the potential for future growth, despite challenges in the reimbursement landscape [42][43] - The company is committed to advancing clinical evidence and believes that the results from ongoing trials will support future guideline considerations and regulatory filings [8][24] Other Important Information - The company has extended its cash runway into the first half of 2027, allowing for continued advancement of clinical programs [12][35] - The FDA has provided feedback that will help streamline the clinical development of VS-7375, with a focus on disease-specific trials [11][59] Q&A Session Summary Question: Insights on NCCN non-update and reimbursement for wild-type patients - Management expressed disappointment regarding the NCCN guidelines and noted that they are actively working to secure reimbursement for wild-type patients, emphasizing ongoing efforts in the commercial setting [41][42] Question: Safety and dose modifications for VS-7375 - Management reported low rates of dose modifications and discontinuations, indicating good tolerability in the U.S. study compared to data from China [47][49] Question: Future financing strategies - The company believes the LGSOC franchise will be self-sustaining and is exploring non-dilutive financing options while being prudent about capital management [62][63] Question: Prescribing dynamics for CO-PACK - The company noted that approximately 75% of top institutions have adopted CO-PACK, with a consistent split of prescriptions between academic and community settings [66]

Financial Data and Key Metrics Changes - The company reported $17.5 million in net product revenue for Q4 2025 and $30.9 million for the full year, marking a successful commercial launch period from May to December 2025 [4][31] - Cost of sales for Q4 2025 was $2.6 million, with total R&D expenses at $31.7 million for the quarter and $114.6 million for the full year [31][32] - The non-GAAP adjusted net loss for Q4 2025 was $39.8 million, compared to a loss of $29.3 million in Q4 2024, indicating increased investment in growth [33] Business Line Data and Key Metrics Changes - The launch of AVMAPKI FAKZYNJA has seen steady growth, with nearly 300 prescribers by February 2026, and over half of prescriptions coming from academic centers [12][66] - The company is focusing on expanding its prescriber base and increasing comfort among oncologists to use the combination therapy [6][12] Market Data and Key Metrics Changes - The NCCN guidelines did not expand recommendations for the treatment to include patients without KRAS mutations, but the company remains confident in its market trajectory [5][41] - The payer coverage for LGSOC-prescribed patients remains strong, with rapid prior authorization approvals leading to prescription fulfillment times of 12-14 days [15][66] Company Strategy and Development Direction - The company aims to maximize the commercial launch of AVMAPKI FAKZYNJA, generate data for VS-7375, and maintain prudent capital management [36][38] - The strategic focus includes expanding the use of the CO-PACK therapy at first recurrence and enhancing educational efforts for healthcare providers [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory and the potential for the LGSOC franchise to become self-sustaining in the second half of 2026 [34][35] - The company is committed to advancing clinical evidence and expanding its pipeline, particularly in RAS-driven cancers [6][10] Other Important Information - The company has extended its cash runway into the first half of 2027, allowing for continued investment in clinical trials and commercial operations [34] - The RAMP 301 Phase 3 trial is expected to report top-line results in mid-2027, which could expand indications for the treatment [22] Q&A Session Summary Question: Insights on NCCN non-update and reimbursement for wild type patients - Management expressed disappointment over the NCCN decision but remains confident in securing reimbursement for wild type patients, emphasizing ongoing efforts to promote the therapy based on clinical data [41][42] Question: Safety and dose selection for VS-7375 - Management reported low dose modifications and discontinuations, with a focus on determining the optimal dose through ongoing evaluations [46][48] - The strategy includes exploring combination therapies with other agents in the RAS space for future positioning [46][51] Question: Future financing strategies - The company believes the LGSOC franchise will be self-sustaining, with any additional capital raised based on positive data from the G12D program [62][64] Question: Next steps for RAMP 201J trial in Japan - The company plans to convert institutions from the 201J study to the confirmatory study and aims to file for conditional approval with the PMDA early next year [85]

Q4 & Full Year 2025 Earnings Call March 4, 2026 Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things, Verastem Oncology's (the "Company") programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJACO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type ...

Financial Performance - The company reported an accumulated deficit of $1,165.0 million as of December 31, 2025, with a net loss of $209.5 million for the year ended December 31, 2025[444]. - Total revenue for the year ended December 31, 2025, was $30.9 million, compared to $10.0 million in 2024, with no product revenue in 2023[499][501]. - The company reported a net loss of $209.5 million for 2025, compared to a net loss of $130.5 million in 2024[500]. - Cash used in operating activities was $137.5 million in 2025, compared to $104.8 million in 2024, largely due to net losses adjusted for non-cash items[519]. - The company expects to incur significant expenses and may continue to experience operating losses, with no profitability expected in the foreseeable future[525]. Research and Development - Research and development expenses totaled $114.6 million for the year ended December 31, 2025, an increase from $81.3 million in 2024 and $61.4 million in 2023[454]. - The company anticipates an increase in research and development expenses in future periods as it continues to develop new treatments and complete ongoing clinical trials[505]. - The total research and development expenses for the product candidates include specific costs for various indications, with the highest being $35.8 million for the LGSOC indication in 2025[454]. - The company is conducting the RAMP 301 Phase 3 trial to evaluate the efficacy of avutometinib plus defactinib, which may expand the indication for treatment beyond KRAS mutation status[440]. Cash and Financing - Cash and cash equivalents were reported at $205.0 million as of December 31, 2025, with an additional $29.4 million received from warrant exercises in January 2026[444]. - The company has financed operations through various means, including public and private stock offerings, convertible notes, and collaboration agreements[443]. - Cash provided by financing activities for the 2025 Period includes $96.9 million from the November 2025 Public Offering and $75.0 million from the Note Purchase Agreement[521]. - The company plans to finance future operations through existing cash, potential future milestones, and product revenues, while also considering strategic financing opportunities[446]. - The company may finance its cash needs through equity offerings, debt financings, and collaborations, which could dilute existing stockholders' ownership[527]. Stock-Based Compensation - For the year ended December 31, 2025, the company recorded $9.4 million of stock-based compensation expense[492]. - As of December 31, 2025, there was approximately $5.4 million of unrecognized stock-based compensation related to stock options, expected to be recognized over a weighted-average period of 2.2 years[492]. - The company evaluates the probability of achieving performance-based milestones for stock-based compensation, which could lead to significant variations in expense recognition[490]. Product Revenue - Product revenue is recognized from AVMAPKI FAKZYNJA CO-PACK sales, with expectations for net product revenues to increase over time despite potential fluctuations in sales allowances[447]. - The company recognizes revenue on sales of AVMAPKI FAKZYNJA CO-PACK when a customer obtains control of the product, typically upon delivery[473]. - The reserves for variable consideration include trade discounts, chargebacks, government rebates, and product returns, which are based on estimates of future outcomes[474]. - The company has not received any product returns as of December 31, 2025[481]. - The company is subject to discount and rebate payment obligations under various government programs, impacting product revenue recognition[477]. Debt and Obligations - The fair value of the Notes at December 31, 2025, was determined to be $76.3 million, differing from the contractual principal amount of $75.0 million by $1.3 million[495]. - The discount rate used for fair value measurement of the Notes was between 12.6%-13.0% at December 31, 2025[495]. - The loss on debt extinguishment for 2025 was $1.8 million, related to the early repayment of a loan agreement[510]. - Interest expense decreased to $1.1 million in 2025 from $4.6 million in 2024, primarily due to the termination of a loan agreement[509]. - The change in fair value of warrant liability resulted in an expense of $27.5 million in 2025, compared to $19.1 million in 2024[512]. Future Outlook - Future capital requirements will depend on various factors, including commercialization costs, clinical trial results, and potential collaborations[528]. - As of December 31, 2025, the company had federal and state NOL carryforwards of $460.5 million and $99.5 million, respectively, available to reduce future taxable income[534]. - The company recorded a 100% valuation allowance against its NOL and tax credit carryforwards, indicating uncertainty in realizing tax benefits[534]. - The company entered into a master services agreement with IQVIA, committing to spend $60.0 million, with $48.1 million remaining unpaid as of December 31, 2025[532]. - The company has borrowed $75.0 million under the Note Purchase Agreement, with interest rates subject to fluctuations based on Term SOFR and a floor of 4.29%[540].